Aurobindo Pharma Ltd
NSE:AUROPHARMA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
989.8
1 568.05
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AUROPHARMA stock under the Base Case scenario is 1 081.41 INR. Compared to the current market price of 1 223.7 INR, Aurobindo Pharma Ltd is Overvalued by 12%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aurobindo Pharma Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AUROPHARMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Aurobindo Pharma Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Aurobindo Pharma Ltd., a prominent player in the global generic pharmaceutical market, began its journey in 1986 with a vision to make high-quality medicines accessible to patients around the world. Over the years, the company has transformed into a diversified pharmaceutical powerhouse, producing a wide range of generic formulations, active pharmaceutical ingredients (APIs), and complex generics. Headquartered in Hyderabad, India, Aurobindo leverages robust research and development capabilities, along with an extensive manufacturing footprint that spans several countries, allowing it to cater to diverse markets, including the United States and Europe. With a commitment to quality and regula...
Aurobindo Pharma Ltd., a prominent player in the global generic pharmaceutical market, began its journey in 1986 with a vision to make high-quality medicines accessible to patients around the world. Over the years, the company has transformed into a diversified pharmaceutical powerhouse, producing a wide range of generic formulations, active pharmaceutical ingredients (APIs), and complex generics. Headquartered in Hyderabad, India, Aurobindo leverages robust research and development capabilities, along with an extensive manufacturing footprint that spans several countries, allowing it to cater to diverse markets, including the United States and Europe. With a commitment to quality and regulatory compliance, Aurobindo's products cover multiple therapeutic areas, including anti-retrovirals, antibiotics, cardiovascular, and central nervous system disorders, making it a well-regarded name in the industry.
For investors, Aurobindo Pharma represents an attractive opportunity, given its consistent revenue growth and strategic focus on innovation. The company's investment in technology and its ability to navigate stringent regulatory landscapes enable it to maintain a competitive edge in the generics sector. Furthermore, Aurobindo's expanding portfolio of complex generics positions it to capture higher margins in the marketplace, while its strong presence in emerging markets ensures ongoing demand for its offerings. As the global healthcare landscape continues to evolve, Aurobindo Pharma's adaptability and commitment to sustainable growth make it a compelling choice for those looking to invest in a resilient and forward-thinking pharmaceutical enterprise.
Aurobindo Pharma Ltd. operates primarily in the pharmaceutical sector, with a strong focus on the following core business segments:
-
Formulations:
- Aurobindo is heavily involved in the development, manufacturing, and marketing of generic formulations. This segment includes various dosage forms such as oral solid dosage (tablets and capsules), injectable formulations, topical products, and more. The company caters to several therapeutic categories, including anti-hypertensives, anti-diabetics, antibiotics, and cardiovascular medications.
-
APIs (Active Pharmaceutical Ingredients):
- The production of APIs is a significant part of Aurobindo's business model. The company manufactures a wide range of APIs, which are essential components in drug formulations. Aurobindo’s capabilities encompass a diverse array of therapeutic segments, providing them with a competitive edge in the generic pharmaceutical market.
-
Over-the-Counter (OTC) Products:
- Aurobindo has a growing portfolio of OTC products, which are available without a prescription. These products generally include vitamins, dietary supplements, and other health-related consumer goods aimed at improving general wellness. This segment is increasingly crucial as consumers seek accessible healthcare solutions.
-
Biosimilars:
- The company has made forays into the biosimilars segment, focusing on the development and commercialization of biologic drugs that are comparable to existing reference biologics in terms of safety, efficacy, and potency. This category targets therapeutic areas such as oncology and immunology.
-
Research and Development (R&D):
- Aurobindo invests heavily in R&D to innovate its product offerings continually. This includes the development of new formulations and improving existing products, which assists in maintaining its market position and meeting regulatory requirements in various global markets.
-
International Market Operations:
- Aurobindo Pharma’s operations extend globally, with a significant share of its business coming from markets in North America, Europe, Africa, Asia, and Latin America. This geographical diversification is critical for mitigating risks associated with regulatory changes and market fluctuations.
Through these core segments, Aurobindo Pharma Ltd. aims to enhance its product offerings and increase market share while maintaining a focus on quality and affordability, reminiscent of the investment principles espoused by Warren Buffett and Charlie Munger, emphasizing long-term business fundamentals and competitive advantages.
Aurobindo Pharma Ltd possesses several unique competitive advantages that distinguish it from its rivals in the pharmaceutical industry:
-
Diverse Product Portfolio: Aurobindo offers a wide range of products, including generic pharmaceuticals, APIs (active pharmaceutical ingredients), and formulations across various therapeutic areas. This diversification helps mitigate risks associated with dependency on a single product line.
-
Strong R&D Capabilities: The company invests significantly in research and development, enabling it to develop complex generics and novel drug formulations. This focus on innovation helps Aurobindo maintain a robust pipeline of products.
-
Cost Efficiency: Aurobindo has built efficient manufacturing processes, leveraging economies of scale and automation. This cost leadership allows the company to offer competitive pricing while maintaining healthy margins.
-
Global Presence and Market Access: Aurobindo operates in multiple international markets, including the US, Europe, and emerging markets. Its established distribution channels and relationships with healthcare providers enhance market access and customer reach.
-
Regulatory Compliance and Quality Standards: The company meets stringent international regulatory requirements, including those from the FDA and EMA. Aurobindo's commitment to high-quality manufacturing standards builds trust with healthcare providers and patients.
-
Strategic Acquisitions and Partnerships: Aurobindo has made strategic acquisitions to enhance its product offerings and expand its market presence. Partnerships with other companies also allow for access to new markets and technologies.
-
Focus on Specialty Products: The company's emphasis on developing specialty pharmaceuticals, including complex generics and biosimilars, positions it favorably in segments with higher barriers to entry, reducing competition.
-
Strong Financial Position: Aurobindo Pharma has a solid balance sheet, enabling continued investments in growth and innovation, while providing stability in a volatile market.
These competitive advantages collectively position Aurobindo Pharma as a formidable player in the pharmaceutical industry, capable of sustaining growth and profitability amidst competitive pressures.
Aurobindo Pharma Ltd, like many pharmaceutical companies, faces a variety of risks and challenges that could impact its performance in the near future. Here are several key considerations:
-
Regulatory Compliance: The pharmaceutical industry is highly regulated, and Aurobindo Pharma must comply with stringent guidelines from regulatory bodies like the FDA, EMA, and others. Any failure to adhere to these regulations could result in penalties, recalls, or bans on product sales.
-
Competition: The generics and specialty pharmaceuticals markets are highly competitive. Aurobindo faces competition from other manufacturers, which could pressure pricing and reduce market share. The entry of new players, especially in emerging markets, further intensifies this competition.
-
Drug Pricing Pressure: There is ongoing pressure from healthcare providers and governments to reduce drug prices, which can impact profitability. The shift towards value-based care and cost containment measures can lead to lower prices for generic drugs.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by the COVID-19 pandemic, can affect raw material availability, production timelines, and distribution. Any disruption in sourcing active pharmaceutical ingredients (APIs) may impact Aurobindo’s ability to manufacture its products.
-
Intellectual Property Challenges: Patent expirations for key products can lead to increased competition from generics. Additionally, challenges from patent litigation can delay product launches and increase legal costs.
-
Product Quality and Safety Issues: Maintaining high product quality is crucial. Any quality issues or safety concerns that lead to recalls can damage reputation and incur significant financial liability.
-
Market Dynamics and Economic Conditions: Economic downturns, changes in healthcare policies, or shifts in demand can affect sales. Aurobindo must also adapt to changing demographics and healthcare trends that impact market demand.
-
Research and Development (R&D) Risks: Dependence on successful R&D efforts for new products introduces risk. Failure to innovate or bring products to market can hinder growth. R&D is capital-intensive and does not guarantee returns.
-
Currency Fluctuations: As a global player, Aurobindo is exposed to foreign exchange risks. Significant currency fluctuations can impact revenues and costs, especially if they operate in diverse markets with various currencies.
-
Public Perception and Corporate Reputation: Any negative publicity regarding labor practices, environmental concerns, or corporate governance can impact Aurobindo’s brand reputation and lead to consumer or investor skepticism.
-
Strategic Execution: The ability to effectively execute strategic initiatives, including mergers and acquisitions, partnerships, and market expansion, is critical. Missteps in strategy could lead to financial losses or operational inefficiencies.
Navigating these challenges will require strategic foresight, robust risk management practices, and a commitment to maintaining high standards in product development, quality assurance, and regulatory adherence.
Revenue & Expenses Breakdown
Aurobindo Pharma Ltd
Balance Sheet Decomposition
Aurobindo Pharma Ltd
Current Assets | 242.1B |
Cash & Short-Term Investments | 65.9B |
Receivables | 48.4B |
Other Current Assets | 127.8B |
Non-Current Assets | 208.7B |
Long-Term Investments | 6.7B |
PP&E | 142.8B |
Intangibles | 40.8B |
Other Non-Current Assets | 18.3B |
Current Liabilities | 122B |
Accounts Payable | 44.5B |
Other Current Liabilities | 77.4B |
Non-Current Liabilities | 30.3B |
Long-Term Debt | 23.9B |
Other Non-Current Liabilities | 6.4B |
Earnings Waterfall
Aurobindo Pharma Ltd
Revenue
|
297.2B
INR
|
Cost of Revenue
|
-125.2B
INR
|
Gross Profit
|
172B
INR
|
Operating Expenses
|
-124.9B
INR
|
Operating Income
|
47.1B
INR
|
Other Expenses
|
-11.9B
INR
|
Net Income
|
35.2B
INR
|
Free Cash Flow Analysis
Aurobindo Pharma Ltd
INR | |
Free Cash Flow | INR |
Aurobindo Pharma experienced significant growth in Q1 FY '25 with a 10% year-on-year increase in revenue, reaching INR 7,567 crores. The U.S. and European markets performed well, with U.S. revenues at $426 million and Europe achieving EUR 221 million. The company maintained an EBITDA margin of 21.4% and net profit rose by 61% to INR 919 crores. Future prospects are optimistic with the expected ramp-up of the Pen-G plant and a target EBITDA margin of 21-22% for FY '25. Key strategic initiatives include new product launches and expanded market presence to drive continued growth and profitability.
What is Earnings Call?
AUROPHARMA Profitability Score
Profitability Due Diligence
Aurobindo Pharma Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Aurobindo Pharma Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
AUROPHARMA Solvency Score
Solvency Due Diligence
Aurobindo Pharma Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Aurobindo Pharma Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AUROPHARMA Price Targets Summary
Aurobindo Pharma Ltd
According to Wall Street analysts, the average 1-year price target for AUROPHARMA is 1 562.17 INR with a low forecast of 1 237.25 INR and a high forecast of 2 026.5 INR.
Dividends
Current shareholder yield for AUROPHARMA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AUROPHARMA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 21,000 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one AUROPHARMA stock under the Base Case scenario is 1 081.41 INR.
Compared to the current market price of 1 223.7 INR, Aurobindo Pharma Ltd is Overvalued by 12%.